PF-Atlas › Clinical Trials › NCT02630316

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Inhaled Treprostinil · Phase 2

Registry ID
NCT02630316
Phase
Phase 2
Status
Completed
Drug / intervention
Inhaled Treprostinil
Sponsor
United Therapeutics
Start
2017-02-03

About this trial

Inhaled Treprostinil is evaluated in NCT02630316, a Phase 2 idiopathic pulmonary fibrosis study sponsored by United Therapeutics. Current status: Completed.

View NCT02630316 on ClinicalTrials.gov →

Explore related

Inhaled Treprostinil / Tyvaso — Treatment profileAll Inhaled Treprostinil trialsAll IPF trials

Related trials

Inhaled Treprostinil — TETON-1Inhaled Treprostinil — TETON-2Inhaled Treprostinil — NCT04905693
Medical disclaimer. This page summarizes public trial data for NCT02630316 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.